Yahoo Finance

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...

TransCode Therapeutics Advances TTX-MC138 After Positive Phase 1a

Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.
Yahoo Finance

TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference

TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics. The Company has created a platform of drug candidates designed to target a ...
Nasdaq

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results Several patients in the first and second cohort remain on ...
Nasdaq

TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment

BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...

TransCode Sets Key Deadlines for 2026 Shareholder Meeting

Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.
Benzinga.com

Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered

TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potential reverse stock split in an open letter to its shareholders. Up Next: Get 5 ...
Benzinga.com

Why Is Brain Cancer Focused TransCode Therapeutics Stock Trading 300% Higher Today?

TransCode Therapeutics Inc (NASDAQ:RNAZ) shares are trading higher after the company announced results with its lead therapeutic candidate, TTX-MC138, in murine models bearing human glioblastoma ...
MarketWatch

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

The MarketWatch News Department was not involved in the creation of this content. BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage ...
Medindia

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2 Several patients in the first and second cohort remain on study for continued ...
Seeking Alpha

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new ...